Ado Trastuzumab Emtansine biosimilar (Hetero Biopharma)

N/A

Report date: 2025/01/16 15:10:47

Base Information

Drug NameAdo Trastuzumab Emtansine biosimilar (Hetero Biopharma)
Drug Alias NameHBP 6
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MCC linker +[4] 
Mechanisms of ActionAnti-HER2Tubulin inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Tubulin
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIndia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesHetero Biopharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHetero Biopharma Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A